$MRK Headlines
U.S. stocks edge higher; S&P 500 hits record 10 min ago - Anora Mahmudova
Short-sellers are all over this market, and that's good news for bulls 23 min ago - blogs.marketwatch.com
Merck to buy Idenix for $3.85 billion 51 min ago - Erin McCarthy
Stock futures off; Family Dollar, Tyson, are active 8:52 a.m. Today - Barbara Kollmeyer
Tyson buys Hillshire; Family Dollar, Idenix surge 8:43 a.m. Today - Saumya Vaishampayan
Merck to buy Idenix for $24.50 per share 7:53 a.m. Today - Ben Eisen
Idenix acquisition delivers Merck hepatitis C portfolio 7:38 a.m. Today - Ben Eisen
Merck buyout values Idenix at $3.85 billion 7:36 a.m. Today - Ben Eisen
Merck to buy Idenix for $24.50 per share 7:35 a.m. Today - Ben Eisen
Merck, Sanofi, Glaxo explore shedding older drugs 5:42 p.m. June 3, 2014 - MarketWatch.com
TripAdvisor leads momentum-play rally to lift Nasdaq 3:52 p.m. May 12, 2014 - Saumya Vaishampayan
Google, Oracle, Merck could follow eBay's move to repatriate cash 9:21 a.m. May 12, 2014 - blogs.marketwatch.com
FDA approves Merck's heart-attack prevention drug 8:39 a.m. May 12, 2014 - MarketWatch
U.S. stocks fall; Nasdaq leads losses 4:37 p.m. May 6, 2014 - Anora Mahmudova
Athenahealth gets ‘Einhorned’; Twitter extends losses 3:47 p.m. May 6, 2014 - Ben Eisen
European stocks fall as OECD calls for ECB action 11:52 a.m. May 6, 2014 - Sara Sjolin
Merck's consumer business sale doesn't help its shares, or Bayer's 11:17 a.m. May 6, 2014 - blogs.marketwatch.com
Newscast: Wall Street reverses course 10:00 a.m. May 6, 2014 - MarketWatch
U.S. stock futures fall; Merck in focus 8:58 a.m. May 6, 2014 - Carla Mozee
Bayer buys Merck’s consumer ops for $14.2 billion 8:23 a.m. May 6, 2014 - Michael Calia
Merck to Buy Idenix for $3.85 Billion 40 min ago - The Wall Street Journal Interactive Edition
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal 8:27 a.m. Today - TheStreet.com
Wall Street Turns Higher 7:28 a.m. Today - FOXBusiness
Stocks Poised to Slip from Record Highs 7:28 a.m. Today - FOXBusiness
3 Dividend Stocks You Can Easily Upgrade 4:05 a.m. Today - InvestorPlace.com
Boring Must Be Good For Your Health 12:13 a.m. June 8, 2014 - Seeking Alpha
The Case for Health-Care Stocks 3:19 p.m. June 6, 2014 - The Wall Street Journal Interactive Edition
4 Cheap Off the Radar Small-Cap Stocks 8:29 a.m. June 5, 2014 - Barrons.com
Top Holdings of Funds 8:18 a.m. June 5, 2014 - Barrons.com
The Nifty Fifty Market 5:20 p.m. June 4, 2014 - Seeking Alpha
Watch Out For The Buyback Taper 11:26 a.m. June 4, 2014 - Seeking Alpha
ObamaCare Seen Boosting Health-Care Stocks 9:37 a.m. June 4, 2014 - The Wall Street Journal Interactive Edition
Sanofi, Merck, Glaxo Considering Deals for Old-Drug Portfolios 5:52 p.m. June 3, 2014 - The Wall Street Journal Interactive Edition
Merck, Sanofi Try to Shed Older Drugs 5:39 p.m. June 3, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Reiterated As A Buy: HAL, MSFT, MRK 4:59 p.m. June 3, 2014 - TheStreet.com
Bayer CEO to Stand Down in 2016 11:40 a.m. June 3, 2014 - The Wall Street Journal Interactive Edition
ASCO 2014 Puts These Biotech Stocks in Focus - Analyst Blog 11:10 a.m. June 3, 2014 - Zacks.com
Teva Acquiring Labrys Biologics For Migraine Drug 10:57 a.m. June 3, 2014 - Investors Business Daily
Dako and Merck Collaborate - Analyst Blog 10:10 a.m. June 3, 2014 - Zacks.com
Experimental Melanoma Treatment Shows Promising Results 10:02 a.m. June 3, 2014 - InvestorPlace.com
Merck to Acquire Idenix 7:30 a.m. Today - BusinessWire - BZX
MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association 8:00 a.m. June 6, 2014 - BusinessWire - BZX
Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association 8:00 a.m. June 6, 2014 - BusinessWire - BZX
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir) 5:00 p.m. June 5, 2014 - BusinessWire - BZX
Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman 9:00 a.m. June 2, 2014 - PR Newswire - PRF
First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 7:33 a.m. June 2, 2014 - BusinessWire - BZX
Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014 7:33 a.m. June 2, 2014 - BusinessWire - BZX
First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014 9:23 a.m. June 1, 2014 - BusinessWire - BZX
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels 9:08 a.m. May 30, 2014 - GlobeNewswire
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels 9:01 a.m. May 30, 2014 - Thomson Reuters ONE
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
MedCPU Closes $9.3 Million in Series B Funding to Expand Clinical Decision Support Solutions for Healthcare Providers 10:01 a.m. May 28, 2014 - BusinessWire - BZX
Critical Alerts For Macy's, Western Digital, InterMune, Merck, and Time Warner Released By InvestorsObserver 9:31 a.m. May 28, 2014 - PR Newswire - PRF
Premier Biomedical Advances New Cancer Treatment Methodology Protocol 9:01 a.m. May 28, 2014 - ACCESSWIRE
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued Commitment to Patients with Relapsing MS 9:00 a.m. May 28, 2014 - PR Newswire - PRF
Merck Announces Third-Quarter 2014 Dividend 12:21 p.m. May 27, 2014 - BusinessWire - BZX
Global Investigator Databank Expands to Five Pharmaceutical Company Members and Announces New Investigator Website 9:00 a.m. May 27, 2014 - PR Newswire - PRF
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019 11:59 a.m. May 21, 2014 - PR Newswire - PRF
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth 8:41 a.m. May 21, 2014 - PR Newswire - PRF
U.S. stocks edge higher; S&P 500 hits record 10 min ago - Anora Mahmudova
Short-sellers are all over this market, and that's good news for bulls 23 min ago - blogs.marketwatch.com
Merck to buy Idenix for $3.85 billion 51 min ago - Erin McCarthy
Stock futures off; Family Dollar, Tyson, are active 8:52 a.m. Today - Barbara Kollmeyer
Tyson buys Hillshire; Family Dollar, Idenix surge 8:43 a.m. Today - Saumya Vaishampayan
Merck to buy Idenix for $24.50 per share 7:53 a.m. Today - Ben Eisen
Idenix acquisition delivers Merck hepatitis C portfolio 7:38 a.m. Today - Ben Eisen
Merck buyout values Idenix at $3.85 billion 7:36 a.m. Today - Ben Eisen
Merck to buy Idenix for $24.50 per share 7:35 a.m. Today - Ben Eisen
Merck, Sanofi, Glaxo explore shedding older drugs 5:42 p.m. June 3, 2014 - MarketWatch.com
TripAdvisor leads momentum-play rally to lift Nasdaq 3:52 p.m. May 12, 2014 - Saumya Vaishampayan
Google, Oracle, Merck could follow eBay's move to repatriate cash 9:21 a.m. May 12, 2014 - blogs.marketwatch.com
FDA approves Merck's heart-attack prevention drug 8:39 a.m. May 12, 2014 - MarketWatch
U.S. stocks fall; Nasdaq leads losses 4:37 p.m. May 6, 2014 - Anora Mahmudova
Athenahealth gets ‘Einhorned’; Twitter extends losses 3:47 p.m. May 6, 2014 - Ben Eisen
European stocks fall as OECD calls for ECB action 11:52 a.m. May 6, 2014 - Sara Sjolin
Merck's consumer business sale doesn't help its shares, or Bayer's 11:17 a.m. May 6, 2014 - blogs.marketwatch.com
Newscast: Wall Street reverses course 10:00 a.m. May 6, 2014 - MarketWatch
U.S. stock futures fall; Merck in focus 8:58 a.m. May 6, 2014 - Carla Mozee
Bayer buys Merck’s consumer ops for $14.2 billion 8:23 a.m. May 6, 2014 - Michael Calia
Merck to Buy Idenix for $3.85 Billion 40 min ago - The Wall Street Journal Interactive Edition
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal 8:27 a.m. Today - TheStreet.com
Wall Street Turns Higher 7:28 a.m. Today - FOXBusiness
Stocks Poised to Slip from Record Highs 7:28 a.m. Today - FOXBusiness
3 Dividend Stocks You Can Easily Upgrade 4:05 a.m. Today - InvestorPlace.com
Boring Must Be Good For Your Health 12:13 a.m. June 8, 2014 - Seeking Alpha
The Case for Health-Care Stocks 3:19 p.m. June 6, 2014 - The Wall Street Journal Interactive Edition
4 Cheap Off the Radar Small-Cap Stocks 8:29 a.m. June 5, 2014 - Barrons.com
Top Holdings of Funds 8:18 a.m. June 5, 2014 - Barrons.com
The Nifty Fifty Market 5:20 p.m. June 4, 2014 - Seeking Alpha
Watch Out For The Buyback Taper 11:26 a.m. June 4, 2014 - Seeking Alpha
ObamaCare Seen Boosting Health-Care Stocks 9:37 a.m. June 4, 2014 - The Wall Street Journal Interactive Edition
Sanofi, Merck, Glaxo Considering Deals for Old-Drug Portfolios 5:52 p.m. June 3, 2014 - The Wall Street Journal Interactive Edition
Merck, Sanofi Try to Shed Older Drugs 5:39 p.m. June 3, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Reiterated As A Buy: HAL, MSFT, MRK 4:59 p.m. June 3, 2014 - TheStreet.com
Bayer CEO to Stand Down in 2016 11:40 a.m. June 3, 2014 - The Wall Street Journal Interactive Edition
ASCO 2014 Puts These Biotech Stocks in Focus - Analyst Blog 11:10 a.m. June 3, 2014 - Zacks.com
Teva Acquiring Labrys Biologics For Migraine Drug 10:57 a.m. June 3, 2014 - Investors Business Daily
Dako and Merck Collaborate - Analyst Blog 10:10 a.m. June 3, 2014 - Zacks.com
Experimental Melanoma Treatment Shows Promising Results 10:02 a.m. June 3, 2014 - InvestorPlace.com
Merck to Acquire Idenix 7:30 a.m. Today - BusinessWire - BZX
MSD to Present New Clinical Data on Sitagliptin, Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association 8:00 a.m. June 6, 2014 - BusinessWire - BZX
Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association 8:00 a.m. June 6, 2014 - BusinessWire - BZX
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS® (raltegravir) 5:00 p.m. June 5, 2014 - BusinessWire - BZX
Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman 9:00 a.m. June 2, 2014 - PR Newswire - PRF
First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014 7:33 a.m. June 2, 2014 - BusinessWire - BZX
Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014 7:33 a.m. June 2, 2014 - BusinessWire - BZX
First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014 9:23 a.m. June 1, 2014 - BusinessWire - BZX
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels 9:08 a.m. May 30, 2014 - GlobeNewswire
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels 9:01 a.m. May 30, 2014 - Thomson Reuters ONE
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
MedCPU Closes $9.3 Million in Series B Funding to Expand Clinical Decision Support Solutions for Healthcare Providers 10:01 a.m. May 28, 2014 - BusinessWire - BZX
Critical Alerts For Macy's, Western Digital, InterMune, Merck, and Time Warner Released By InvestorsObserver 9:31 a.m. May 28, 2014 - PR Newswire - PRF
Premier Biomedical Advances New Cancer Treatment Methodology Protocol 9:01 a.m. May 28, 2014 - ACCESSWIRE
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued Commitment to Patients with Relapsing MS 9:00 a.m. May 28, 2014 - PR Newswire - PRF
Merck Announces Third-Quarter 2014 Dividend 12:21 p.m. May 27, 2014 - BusinessWire - BZX
Global Investigator Databank Expands to Five Pharmaceutical Company Members and Announces New Investigator Website 9:00 a.m. May 27, 2014 - PR Newswire - PRF
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019 11:59 a.m. May 21, 2014 - PR Newswire - PRF
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth 8:41 a.m. May 21, 2014 - PR Newswire - PRF
